

# Endothelial Nitric Oxide Synthase Uncoupling Impairs Endothelial Progenitor Cell Mobilization and Function in Diabetes

Thomas Thum,<sup>1</sup> Daniela Fraccarollo,<sup>1</sup> Maximilian Schultheiss,<sup>1</sup> Sabrina Froese,<sup>1</sup> Paolo Galuppo,<sup>1</sup> Julian D. Widder,<sup>1,2</sup> Dimitrios Tsikas,<sup>3</sup> Georg Ertl,<sup>1</sup> and Johann Bauersachs<sup>1</sup>

**Uncoupling of the endothelial nitric oxide synthase (eNOS) resulting in superoxide anion ( $O_2^-$ ) formation instead of nitric oxide (NO) causes diabetic endothelial dysfunction. eNOS regulates mobilization and function of endothelial progenitor cells (EPCs), key regulators of vascular repair. We postulate a role of eNOS uncoupling for reduced number and function of EPC in diabetes. EPC levels in diabetic patients were significantly reduced compared with those of control subjects. EPCs from diabetic patients produced excessive  $O_2^-$  and showed impaired migratory capacity compared with nondiabetic control subjects. NOS inhibition with  $N^G$ -nitro-L-arginine attenuated  $O_2^-$  production and normalized functional capacity of EPCs from diabetic patients. Glucose-mediated EPC dysfunction was protein kinase C dependent, associated with reduced intracellular  $BH_4$  (tetrahydrobiopterin) concentrations, and reversible after exogenous  $BH_4$  treatment. Activation of NADPH oxidases played an additional but minor role in glucose-mediated EPC dysfunction. In rats with streptozotocin-induced diabetes, circulating EPCs were reduced to  $39 \pm 5\%$  of controls and associated with uncoupled eNOS in bone marrow. Our results identify uncoupling of eNOS in diabetic bone marrow, glucose-treated EPCs, and EPCs from diabetic patients resulting in eNOS-mediated  $O_2^-$  production. Subsequent reduction of EPC levels and impairment of EPC function likely contributes to the pathogenesis of vascular disease in diabetes. *Diabetes* 56: 666–674, 2007**

From the <sup>1</sup>Universität Würzburg, Universitätsklinikum, Medizinische Klinik I, Würzburg, Germany; the <sup>2</sup>Division of Cardiology, Emory School of Medicine, Atlanta, Georgia; and the <sup>3</sup>Institute for Clinical Pharmacology, Medical School Hannover, Hannover, Germany.

Address correspondence and reprint requests to Dr. med. Thomas Thum or PD Dr. med. Johann Bauersachs, Universitätsklinikum, Medizinische Klinik I, Josef-Schneider Str. 2, 97080 Würzburg, Germany. E-mail: thum\_t@klinik.uni-wuerzburg.de or bauersachs\_j@medizin.uni-wuerzburg.de.

Received for publication 22 May 2006 and accepted in revised form 12 December 2006.

$BH_4$ , tetrahydrobiopterin; CFU, colony forming unit; EBM, endothelial basal medium; eNOS, endothelial nitric oxide synthase; EPC, endothelial progenitor cell; HPLC, high-performance liquid chromatography; L-NNA,  $N^G$ -nitro-L-arginine; PBMC, peripheral blood mononuclear cell; PKC, protein kinase C; ROS, reactive oxygen species.

DOI: 10.2337/db06-0699

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**C**ardiovascular disease is a common complication of diabetes (1,2). Endothelial dysfunction as a first step in the pathogenesis of diabetes promotes arteriosclerosis (3). Mechanistically, uncoupling of the endothelial nitric oxide synthase (eNOS) in blood vessels of diabetic patients leads to excessive superoxide anion ( $O_2^-$ ) production and diminishes nitric oxide (NO) availability (4–6). The underlying molecular events are not completely clear, but reduction of the essential eNOS cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin ( $BH_4$ ) and involvement of the protein kinase C (PKC) in exaggerated  $O_2^-$  production have been proposed (4,7).

Endothelial progenitor cells (EPCs) are bone marrow-born cells with the potential to differentiate into functional mature endothelial cells, which can substitute diseased endothelium (8). Decreased levels of circulating EPCs are correlated with increased risk for coronary artery disease and myocardial infarction (9–12). Reduced levels of EPCs have been described in both type 1 and type 2 diabetic patients (13,14). EPC recruitment for re-endothelialization after vascular injury is impaired in diabetes (15). These alterations are likely to be involved in the pathogenesis of vascular disease in diabetes (16). Although eNOS is of paramount importance for the regulation of mobilization and function of EPCs (17,18), data concerning the role of eNOS uncoupling in diabetic EPCs are not available.

EPCs are embedded in a microenvironment of bone marrow stromal and endothelial cells and can be translocated to the circulation. NO-mediated signaling pathways have been previously proposed to be essential for EPC mobilization (17,19). Whether these pathways are altered in diabetic bone marrow is not known.

We tested our hypothesis that eNOS uncoupling occurs in EPCs from diabetic patients and is involved in impaired cellular function. We also investigated a potential mechanistic role of  $BH_4$  and PKC signaling in glucose-mediated eNOS uncoupling in EPCs. Finally, we analyzed whether low circulating EPC levels observed in diabetes may result from alterations in bone marrow EPC mobilizing pathways.

## RESEARCH DESIGN AND METHODS

The study conforms to the *Guide for the Care and Use of Laboratory Animals* published by the U.S. National Institutes of Health (publ. no. 85-23, revised 1996). Clinical study approval from the ethics committee of the University of Würzburg was obtained, as was informed written consent from patients.

TABLE 1  
Patient characteristics

|                                    | Type 2 diabetic patients | Nondiabetic control subjects |
|------------------------------------|--------------------------|------------------------------|
| <i>n</i>                           | 5                        | 5                            |
| Sex (male/female)                  | 2/3                      | 2/3                          |
| Age (years)                        | 70.6 ± 1.7               | 70.0 ± 2.9                   |
| Glucose (mg/dl)                    | 294 ± 32.0               | 100 ± 6.4                    |
| A1C (%)                            | 8.8 ± 0.59               | 5.4 ± 0.06                   |
| Hypertension                       | 3                        | 3                            |
| Coronary artery disease medication | 1                        | 1                            |
| Aspirin                            | 1                        | 2                            |
| β-Blocker                          | 3                        | 3                            |
| ACE inhibitor                      | 2                        | 2                            |
| Statin                             | 2                        | 2                            |

Data are means ± SEM or *n*.

**Isolation of bone marrow and peripheral blood mononuclear cells.** We isolated peripheral blood mononuclear cells (PBMCs) derived from leucopheresis material of healthy volunteers or from whole blood of type 2 diabetic (*n* = 5, aged 70.6 ± 1.7 years) and nondiabetic (*n* = 5, aged 70.0 ± 2.9 years) patients, as described (11). Glucose concentrations and A1C values were determined in the morning after an overnight fasting period. Detailed patient characteristics are shown in Table 1. As diabetes had not been diagnosed previously in these patients, they were not on insulin or any oral antidiabetes medication at the time of blood withdrawal. Rat PBMCs were isolated by Ficoll density centrifugation (20). Hollow bones of rat legs were prepared by standard surgical procedures, and whole bone marrow was harvested by flushing marrow with 500 μl PBS using a syringe with a 20-gauge needle as described (20). Bone marrow was pelleted and shock frozen before further analysis.

**Determination of endothelial progenitor cell numbers and cellular characterization.** We used an adhesion-related selection method for isolation of monocytic EPCs, as described (11,15,20,21). PBMCs ( $2 \times 10^5$ ) were cultured on fibronectin-precoated eight-well chamber slides (Lab-Tek; Nunc, Wiesbaden, Germany) in endothelial basal medium (EBM)-2 culture medium supplemented with EBM SingleQuots (Cambrex, Verviers, Belgium) and 20% fetal calf serum for 3 days. To exclude contamination with mature circulating endothelial cells, we carefully removed culture supernatant 2 h after initial seeding and placed it on new fibronectin-precoated chamber slides. EPCs were characterized by cellular uptake of acetylated LDL (dil-acLDL; Molecular Probes, Eugene, Oregon), binding of fluorescein isothiocyanate-conjugated lectin from *Ulex europaeus* (UEA-1; Sigma, Deisenhofen, Germany), expression of vascular endothelial growth factor receptor-2 and eNOS, capacity for integration during endothelial tube formation, and cellular migration and colony forming unit (CFU) capacity, as described (20). Additionally, EPCs were stained with an anti-von Willebrand factor antibody (Sigma).

**Animal study protocol.** Diabetes was induced by a single intravenous injection of streptozotocin (50 mg/kg) in male Wistar rats (180–200 g) obtained from Harlan-Winkelmann (Borchen, Germany). After 12 weeks hyperglycemia was confirmed by a blood glucose monitoring system in the morning after an overnight fasting period (Ascensia Elite; Bayer, Leverkusen, Germany). Only streptozotocin-induced diabetic rats with blood glucose levels >300 mg/dl were included in the study.

**Western blot analyses and enzyme-linked immunosorbent assay.** Western blotting was performed as described (22). In brief, cell extracts were mixed with sample loading buffer and separated under reducing conditions on 12% SDS-polyacrylamide gel. Proteins were electro-transferred onto polyvinylidene fluoride membranes (Immun-Blot 0.2 μm; Bio-Rad), incubated for 2 h in Tris-buffered saline with Tween (TBS-T) with 5% blocking agent (Amersham), and then incubated overnight at 4°C with primary antibodies. The bands were detected using a chemiluminescence assay (ECL+Plus; Amersham). Primary antibodies used included mouse anti-eNOS and anti-phospho-eNOS (Transduction Laboratories, BD Biosciences, Heidelberg, Germany) and mouse anti-GAPDH (Abcam, Acris, Germany).

**Low-temperature SDS-PAGE.** Cell extracts were mixed with 3× SDS sample buffer (187.5 mmol/l Tris-HCl [pH 6.8], 6% wt/vol SDS, 30% glycerol, 0.03% wt/vol bromophenol blue, and 15% vol/vol 2-mercaptoethanol) at 0°C. Samples were loaded on 7.5% polyacrylamide gels and subjected to electro-

phoresis. Gels and buffers were cooled to 4°C before electrophoresis and the buffer tank placed in an ice bath during electrophoresis. eNOS dimer/monomer protein was detected by Western blot analysis.

**Detection of reactive oxygen species in total bone marrow and EPCs.** A variety of different techniques were used to measure reactive oxygen species (ROS) production, as described below.

**Detection of malondialdehyde in bone marrow.** Malondialdehyde-thio-barbituric acid adducts were measured by high-performance liquid chromatography (HPLC) as described (23). Bone marrow supernatants were separated, and fractionation of the protein-free extract was performed using a C18 column (Micro Bondapak; Waters, Milford, MA) in an HPLC system (Pharmacia LKB, Freiburg, Germany). We used a flow rate of 1 ml/min at a pressure of 1,800 psi at 35°C. Exact quantification was achieved using 1,1,3,3-tetraethoxypropane standards.

**Determination of superoxide anions by lucigenin-enhanced chemiluminescence.** Superoxide anion formation was measured by lucigenin-enhanced chemiluminescence. Cell extracts were transferred into scintillation vials containing lucigenin and Krebs/HEPES buffer (final composition: 0.005 mmol/l lucigenin, 99.01 mmol/l NaCl, 4.69 mmol/l KCl, 2.5 mmol/l CaCl<sub>2</sub>, 1.2 mmol/l MgSO<sub>4</sub>, 1.03 mmol/l KH<sub>2</sub>PO<sub>4</sub>, 25 mmol/l NaHCO<sub>3</sub>, 20 mmol/l Na-HEPES, and 5.6 mmol/l glucose [pH 7.4]). Signals were assessed over 20 min in a luminometer (Wallac, Freiburg, Germany) at 30-s intervals. To address the effects of NOS inhibition on superoxide production, aliquots of bone marrow extracts were incubated with N<sup>G</sup>-nitro-L-arginine (L-NNA, 1 mmol/l) for 20 min.

**Dihydroethidium assay.** The redox-sensitive, cell-permeable fluorophore dihydroethidium becomes oxidized in the presence of O<sub>2</sub><sup>-</sup> to yield fluorescent ethidium. Thus, dye oxidation is an indirect measure of the presence of reactive oxygen intermediates. Cultured EPCs were incubated with dihydroethidium (2.5 μmol/l) for 30 min. After washing mean channel fluorescence, each sample was measured during fluorescence-microscopic evaluation of at least four different visual fields. Intracellular ROS in human EPCs were additionally detected using a FACSCalibur flow cytometer (Becton Dickinson, San Juan, CA). Fluorescence was measured using an FL-3 filter (670 nm), and histograms of 10,000 events were analyzed per experiment. The degree of fluorescence in EPCs was then evaluated using Cell Quest software (Becton Dickinson).

**Detection of reactive nitrogen species in EPCs**

**3-Nitrotyrosine assay.** Peroxynitrite reacts quickly with a variety of different biomolecules to produce 3-nitrotyrosine, which therefore is a good biomarker for reactive nitrogen species (24). Human EPCs were treated with glucose (30 mmol/l, 24 h), and then cell lysates were prepared on ice using cell lysis buffer (1 mol/l Tris-HCl [pH 7.6], 0.5 mol/l EDTA, and 1.25 mol/l dithiothreitol). 3-Nitrotyrosine from cell lysates was then isolated by HPLC and subjected to a sensitive gas chromatography-tandem mass spectrometry method, as recently described by us (24), in the electron capture negative-ion chemical ionization mode on a triple-stage quadrupole mass spectrometer model ThermoQuest TSQ 7,000 (Finnigan MAT, San Jose, CA) directly interfaced with a Trace 2000 series gas chromatograph equipped with an autosampler AS 2000 (CE Instruments, Austin, TX) (24).


**Measurements of biopterin content in EPCs.** Measurements of biopterin content in EPCs were performed using HPLC analysis and a differential oxidation method as previously described (25). The amount of BH<sub>4</sub> was determined from the difference between total (BH<sub>4</sub> plus BH<sub>2</sub> plus biopterin) and alkaline-stable oxidized (BH<sub>2</sub> plus biopterin) biopterin. A Nucleosil C-18 column (4.6 × 250 mm, 5 μm) was used with 5% methanol/95% water as a solvent at a flow rate of 1.0 ml/min. The fluorescence detector was set at 350 nm for excitation and 450 nm for emission.

**Functional analysis of EPCs**

**CFU assay.** Endothelial CFUs from isolated PBMCs of diabetic and nondiabetic patients were determined using the EndoCult system (StemCell Technologies) as described (11).

**Migration assay.** Migratory capacity of EPCs was investigated using the modified Boyden chamber assay as previously described (11,20). After treatment,  $5 \times 10^4$  EPCs were cultured in inlets (Falcon HTS Fluoro Blok insert, 8-μm pore size), which were placed in 24-well culture dishes containing EBM (Clonetics) and 50 ng/ml vascular endothelial growth factor, and 100 ng/ml stromal cell-derived factor-1. After 24 h, migrated cells were stained with dil-acLDL and manually counted by fluorescence-based microscopic evaluation of the bottom side of the membrane.

**Statistical analysis.** Data are expressed as means ± SEM. Statistical analysis was performed by one-way ANOVA followed by multiple comparisons using Fisher's protected least significant difference test. Statistical analysis was performed using StatView 5.0 statistic program (Abacus Concepts, Berkeley, CA). Statistical significance was assumed at *P* < 0.05.




**FIG. 1.** Circulating endothelial progenitor cells are reduced in diabetic patients. *A* and *B*: Number of endothelial CFUs in diabetic patients and nondiabetic control subjects. *C* and *D*: Characterization of monocytic endothelial progenitor cells (labeled in red) based on their ability to migrate toward an vascular endothelial growth factor/stromal cell-derived factor-1 gradient (*C*) and to incorporate/adhere during vascular network formation on matrigel when cocultured with human umbilical vein endothelial cells (labeled in green, *D*) (see ref. 11 for details). *E*: Expression of the von Willebrand (vWF) factor in EPCs, including formation of typical Weibel-Palade Bodies (intense green spots). Figures *E-H* show vWF expression (*E*), Dil-acLDL uptake (*F*), nuclear staining by DAPI (*G*), and merged pictures (*H*). Data of endothelial CFUs represent means  $\pm$  SEM.  $n = 5$  measurements per group.

## RESULTS

**Reduced numbers and impaired function of EPCs from diabetic patients: evidence for eNOS uncoupling.** Diabetic patients were characterized by increased plasma glucose concentration ( $294.0 \pm 32.0$  vs.  $100.0 \pm 6.4$  mg/dl) and increased A1C values ( $8.8 \pm 0.6$  vs.  $5.4 \pm 0.1\%$ ) compared with nondiabetic age-matched subjects. Patient characteristics are shown in Table 1.

Diabetic patients had reduced formation of endothelial CFUs compared with nondiabetic subjects ( $9.8 \pm 1.9$  vs.  $22.6 \pm 1.7$  CFUs,  $P = 0.001$ ; Fig. 1*A* and *B*). A detailed

description of human EPC characterization has been previously published (11) (Fig. 1). EPCs from diabetic patients displayed increased ROS formation ( $11.7 \pm 0.7$  vs.  $6.2 \pm 1.1$  arbitrary units,  $P < 0.001$ ; Fig. 2*A* and *B*) but impaired migratory capacity compared with EPCs from nondiabetic age-matched subjects ( $40.4 \pm 4.6$  vs.  $72.7 \pm 6.2$  migrated cells,  $P < 0.0001$ ; Fig. 2*C*). After NOS inhibition with L-NNA in EPCs from diabetic patients, ROS production was attenuated and cellular migration improved by  $34.6 \pm 5.6\%$  ( $P < 0.05$ ; Fig. 2*A-C*). Incubation of diabetic EPCs with pegylated superoxide dismutase com-



**FIG. 2.** Uncoupling of eNOS leads to ROS-mediated EPC dysfunction in diabetic patients. FACS analysis demonstrating intracellular ROS levels (A and B) and migratory capacity (C) of isolated EPCs from healthy control subjects and diabetic patients. A subgroup of EPCs from diabetic patients was additionally pretreated with superoxide dismutase (SOD) or L-NNA. \* $P < 0.05$ , \*\* $P < 0.001$ , \*\*\* $P < 0.0001$ ; † $P < 0.0001$  vs. diabetic EPCs. Data represent means  $\pm$  SEM.  $n = 5$  measurements per group.

pletely inhibited ROS formation and improved migration by  $60.1 \pm 11.3\%$  ( $P < 0.001$ ; Fig. 2A–C).


**Uncoupling of eNOS and ROS-mediated EPC dysfunction in cultured EPCs by glucose treatment: effects of PKC inhibition and tetrahydrobiopterin (BH<sub>4</sub>) treatment.** To test whether observations from the clinical study can be related to the increased glucose concentration in patients, we carried out further in vitro studies. Glucose treatment increased ROS production up to threefold and impaired migratory capacity of cultured EPCs by  $55.7 \pm 8.2\%$  ( $P < 0.001$ ), whereas treatment with mannitol (30 mmol/l) as osmotic control had no effect (Fig. 3A and B). Increased concentrations of O<sub>2</sub><sup>-</sup> react with NO in a reaction forming peroxynitrite, the latter being a powerful toxicant to a wide range of cells (26). Peroxynitrite is difficult to measure and reacts quickly with a variety of different biomolecules to produce 3-nitrotyrosine. In glucose-challenged EPCs, 3-nitrotyrosine concentration was substantially higher than in control subjects, whereas NOS and to a lesser extent NADPH oxidase inhibition attenuated exaggerated 3-nitrotyrosine production (Fig. 3C). Combined NOS and NADPH oxidase inhibition completely inhibited 3-nitrotyrosine production in glucose-challenged EPCs (Fig. 3C).

The glucose-mediated impairment of EPC migration was diminished when cells were concomitantly treated with

pegylated superoxide dismutase (Fig. 3B). Inhibition of NOS with L-NNA attenuated the detrimental effects of glucose (Fig. 3A and B).

Because PKC is involved in vascular O<sub>2</sub><sup>-</sup> in diabetic vessels (4), we analyzed its importance in glucose-mediated ROS production in EPCs. Inhibition of PKC by chelerythrine attenuated O<sub>2</sub><sup>-</sup> production after treatment of EPCs with glucose. In parallel, EPC function was improved (Fig. 3A and B). PKC may also activate NADPH oxidases (27); therefore, we additionally tested the contribution of NADPH oxidases in glucose-mediated impairment of EPCs. Inhibition of NADPH oxidases resulted in a slight reduction of intracellular O<sub>2</sub><sup>-</sup> levels after glucose challenge, whereas combined inhibition of NOS and NADPH oxidases strongly lowered O<sub>2</sub><sup>-</sup> production. A trend for improved migratory capacity was also observed after concomitant treatment with glucose and DPI, although this was not statistically significant. However, synergistic effects on the improvement of EPC migration after glucose challenge were observed after combined treatment with L-NNA and DPI (Fig. 3).

In addition, a reduction of the essential eNOS cofactor BH<sub>4</sub> has been described to be mechanistically involved in eNOS uncoupling (4,7). Intracellular levels of BH<sub>4</sub> and total and oxidized biopterin levels were measured in lysates from glucose-challenged and control EPCs. Glu-



**FIG. 3.** Glucose treatment leads to eNOS uncoupling and impaired migratory capacity of EPC. **A:** Detection of fluorescent ethidium after staining of cultured EPCs with the redox-sensitive, cell-permeable fluorophore dihydroethidium. **B:** Migratory capacity of EPCs. EPCs were treated with ascending doses of glucose, glucose + superoxide dismutase (SOD), glucose + L-NNA, glucose + the PKC inhibitor chelerythrine, glucose + the NADPH oxidase inhibitor DPI or mannitol. **C:** Free 3-nitrotyrosine levels in EPC lysates after treatment with glucose (24 h, 30 mmol/l). \* $P < 0.001$ , \*\* $P < 0.0001$ , † $P < 0.05$  vs. 30 mmol/l glucose, †† $P < 0.01$  vs. 30 mmol/l glucose, ††† $P < 0.0001$  vs. 30 mmol/l glucose. Data represent means  $\pm$  SEM.  $n = 4$ –6 measurements per study group.

cose treatment significantly reduced the concentration of intracellular  $BH_4$  by 59%, whereas oxidized biopterin levels raised by 36% ( $P < 0.05$ ). Total biopterin levels were basically unchanged (Fig. 4A and B). To test whether

reversal of the glucose-mediated reduction in intracellular  $BH_4$  levels would rescue EPC function, we performed further studies. Exogenous treatment of glucose-challenged EPCs with  $BH_4$  increased their intracellular avail-




FIG. 4. BH<sub>4</sub>-dependent rescue of glucose-mediated EPC dysfunction. Detection of intracellular BH<sub>4</sub> levels (A), total biopterin (B), alkaline-stable oxidized biopterin (BH<sub>2</sub> plus biopterin) (C), superoxide anions (D), and measurement of migratory capacity (E) of EPCs. EPCs were treated with glucose or glucose + BH<sub>4</sub> (10  $\mu$ mol/l). Each  $n = 4-6$  experiments. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; †† $P < 0.01$  vs. glucose, ††† $P < 0.001$  vs. glucose. Data represent means  $\pm$  SEM.

ability by fivefold compared with untreated controls. As a result, glucose-mediated exaggerated O<sub>2</sub><sup>-</sup> production was attenuated and EPC migratory capacity significantly improved (Fig. 4C and D).

**eNOS uncoupling in bone marrow in experimental diabetes: consequence for circulating EPCs.** To understand whether reduced levels of EPCs in diabetes are potentially mediated by changes of EPC-mobilizing pathways in bone marrow, we used rats with streptozotocin-induced diabetes. Diabetic animals had higher serum glucose levels compared with control animals ( $459 \pm 39$  vs.  $151 \pm 15$  mg/dl,  $P < 0.0001$ ). In contrast, levels of circulating EPCs were reduced to  $39 \pm 5\%$  compared with nondiabetic animals ( $P < 0.05$ ) (Fig. 5A). A detailed rat EPC characterization has been previously published (20).

Diabetes was associated with 4.9-fold increased malondialdehyde-thiobarbituric acid adduct formation, an index of ROS generation (data not shown), as well as with increased O<sub>2</sub><sup>-</sup> production in bone marrow (Fig. 5B and C). eNOS protein expression was increased in bone marrow extracts of diabetic rats (Fig. 5D), whereas eNOS phosphorylation (Fig. 5E), as well as eNOS dimer-to-monomer ratio, was reduced (Fig. 5F). NOS inhibition by L-NNA

increased O<sub>2</sub><sup>-</sup>-mediated chemiluminescence in bone marrow extracts from control subjects but decreased O<sub>2</sub><sup>-</sup> levels in diabetic bone marrow, indicating uncoupling of eNOS to be involved in exaggerated O<sub>2</sub><sup>-</sup> production (Fig. 5C).

## DISCUSSION

Diabetic patients are at high risk for endothelial lesions and arteriosclerosis. EPCs essentially contribute to vascular lesion repair (8). In the present study, we demonstrate for the first time uncoupling of the eNOS in EPCs from diabetic patients, in glucose-treated EPCs, and in bone marrow from diabetic rats. eNOS uncoupling explains at least in part reduced levels and impaired function of EPCs observed in diabetes and provides a valuable pharmacological target.

Under physiological conditions, eNOS confers anti-arteriosclerotic vascular protection (28). Indeed, eNOS-deficient mice display enhanced onset and rapid progression of arteriosclerosis (29). Exogenous NO may reverse the migratory defect of EPCs associated with diabetes (30). In general, increased eNOS expression is considered to be




FIG. 5. Reduced circulating EPCs and eNOS uncoupling in bone marrow in rats with streptozotocin-induced diabetes. *A*: Circulating endothelial progenitor cells ( $n = 6$  controls,  $n = 7$  diabetic animals). *B* and *C*: Superoxide anion production in bone marrow extracts assessed by lucigenin ( $5 \mu\text{mol/l}$ )-enhanced chemiluminescence (*B*) and percentage of change after addition of L-NNA ( $1 \text{ mmol/l}$ ) (*C*). *D* and *E*: eNOS protein expression (*D*) and eNOS phosphorylation as revealed by Western blot analysis (*E*). *F*: eNOS dimer-to-monomer ratio. Control = control rats,  $n = 7$ ; diabetes = rats with streptozotocin-induced diabetes,  $n = 7$ .  $\dagger P < 0.05$ ,  $\dagger\dagger P < 0.001$  vs. control.

beneficial. However, under certain pathophysiological conditions, upregulation of eNOS expression is associated with reduced endothelium-dependent vasodilatation (31–34) explained by the so-called “eNOS uncoupling” (rev. in 7,33,34). Under this condition eNOS itself can be a source of  $\text{O}_2^-$ , instead of NO (7,31–34). eNOS uncoupling was shown in a variety of experimental and clinical vascular disease states, especially in diabetes (6,7,33,35). Diabetes-associated eNOS uncoupling has been described in the heart, vessels, and the kidney (4,34–39), resulting in decreased NO bioavailability, increased superoxide production, and disrupted eNOS dimer formation within the vascular wall, while eNOS mRNA and/or protein levels are maintained or even increased (36–38). A reduction of the essential eNOS cofactor  $\text{BH}_4$  has been described to be

mechanistically involved in eNOS uncoupling (7,31,35, 37,40).

In our present study, EPCs from diabetic patients had increased intracellular ROS levels, reduced endothelial CFU capacity, and impaired migratory function, which were improved after NOS inhibition. In vitro, high glucose concentration led to increased ROS production and 3-nitrotyrosine levels and impairment of EPC function in EPCs. While EPCs are equipped with powerful antioxidative enzyme systems that may reduce the damaging effects of ROS (41), a direct correlation between functional capacity of EPCs and intracellular ROS production recently has been proposed (42,43). Glutathione peroxidase-1-deficient mice had increased ROS production and suffered from impaired migratory capacity of EPCs and

reduced angiogenesis in vitro (42). The protective role of eNOS may only be maintained under a normoglycemic environment, as under hyperglycemic conditions eNOS has been shown to become uncoupled to produce  $O_2^-$  (4–7). Addition of superoxide dismutase, which highly efficiently detoxifies  $O_2^-$ , completely normalized ROS production and EPC function. As NOS inhibition only partly attenuated  $O_2^-$  production, other systems may also be involved in ROS production and EPC dysfunction in a diabetic environment, such as excessive mitochondrial production of ROS (42) or increased activation of the p38 MAP kinase in EPCs (44). However, eNOS uncoupling in EPCs as shown in the present study seems to play an important and dominant role in glucose-mediated EPC dysfunction.

The underlying molecular mechanisms by which increased ROS may disturb EPC function are unclear, but reduced bioavailability of NO or the eNOS cofactor  $BH_4$  may be involved (7,17,20,29,40). Indeed, intracellular  $BH_4$  levels depend by large on their degradation due to excessive oxidation (rev. in 7). Reduced  $BH_4$  levels have been reported in diabetic eNOS uncoupling (7,31,35), and restoration of  $BH_4$  levels can “recouple” eNOS and enhance its regular enzymatic activity (7,40). In the present study we demonstrate for the first time a critical role for intracellular  $BH_4$  levels for coupling and uncoupling of eNOS in EPCs. Indeed, we observed a significant reduction of intracellular  $BH_4$  levels after challenging EPCs with high concentrations of glucose, whereas oxidized bipterin levels were significantly increased. This switch from  $BH_4$  levels to oxidized bipterin strengthens our results that during glucose challenge eNOS in EPCs becomes uncoupled. Strikingly, addition of exogenous  $BH_4$  resulted in reduction of intracellular  $O_2^-$  levels and complete rescue of EPC function during high-dose glucose treatment.

PKC is involved in the vascular  $O_2^-$  production in diabetic vessels (4). Its inhibition restores vascular NO bioavailability and endothelial function (4), but a role in EPCs has not been investigated so far. We demonstrate PKC to be essential in translation of the detrimental effects of high levels of glucose to EPCs. PKC inhibition resulted in reduced glucose-mediated  $O_2^-$  production and improvement of EPC function, suggesting a potential therapeutic role of PKC inhibitors in dysfunctional EPCs.

While reduced circulating EPC levels in diabetes have been observed in several human studies (13–14,45,46), alterations in EPC mobilizing pathways within diabetic bone marrow have not been identified so far. A pivotal role for eNOS in the regulation of EPC mobilization was shown with eNOS-deficient mice, which show impaired capacity to mobilize EPCs and impaired function of isolated EPCs (17). In the bone marrow, eNOS is the uniquely expressed NOS isoform, whereas iNOS or neuronal NOS are not detected (47). We observed enhanced eNOS expression in the bone marrow of diabetic rats, whereas eNOS monomerization and superoxide anion production were increased.  $O_2^-$  production was blocked upon NOS inhibition. Our data therefore provide evidence for eNOS uncoupling within bone marrow in diabetes. The uncoupling of eNOS has previously been linked to its monomerization upon treatment of endothelial cells with peroxynitrite or glucose (37,48). In diabetic bone marrow, eNOS dimer-to-monomer ratio was shifted to monomerization. Changes in the dimer-to-monomer ratio are not directly linked to functional uncoupling of eNOS, as only the dimeric form appears to be biochemically active and is able to generate

either NO or  $O_2^-$ . However, the eNOS monomer can be viewed as a marker for eNOS uncoupling (5). eNOS uncoupling in bone marrow lowers NO bioavailability and thus likely contributed to the observed reduced levels of circulating EPCs.

We cannot rule out that other  $O_2^-$ -producing systems play an additional role in the observed effects. For instance, we also observed a minor contribution of NADPH oxidases in glucose-mediated increase in ROS formation and subsequent reduction in EPC function. However, a stronger attenuation of  $O_2^-$  formation was observed after eNOS inhibition, indicating a major role for uncoupled eNOS in superoxide production in diabetes.

In conclusion, eNOS uncoupling impairs EPC number and function in diabetes, thus contributing to the pathogenesis of vascular disease.

#### ACKNOWLEDGMENTS

This work was supported in part by the IZKF Würzburg (D22 to J.B.; E-31 Nachwuchsgruppe Cardiac Wounding and Healing to T.T.), the Novartis Foundation (to T.T. and J.B.), and the Ernst und Berta Grimmke-Stiftung (to T.T.). J.D.W. was supported by the Deutsche Akademie der Naturforscher Leopoldina (BMBF-LPD 9901/8-97).

The authors thank Helga Wagner (University of Würzburg) and Anja Mitschke (Medical School Hannover) for expert technical assistance.

#### REFERENCES

- Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. *JAMA* 241:2035–2038, 1979
- Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 348:383–393, 2003
- Feener EP, King GL: Vascular dysfunction in diabetes mellitus. *Lancet* 350 (Suppl. 1):S19–S13, 1997
- Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res* 88:14–22, 2001
- Bauersachs J, Schaefer A: Tetrahydrobiopterin and eNOS dimer/monomer ratio: a clue to eNOS uncoupling in diabetes? *Cardiovasc Res* 65:768–769, 2005
- Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. *Circulation* 105:1656–1662, 2002
- Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Circulation* 113:1708–1714, 2006
- Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 85:221–228, 1999
- Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 348:593–600, 2003
- Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. *Circulation* 111: 2981–2987, 2005
- Thum T, Tsikas T, Stein S, Schultheiss M, Eigenthaler M, Anker SD, Poole-Wilson PA, Ertl G, Bauersachs J: Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. *J Am Coll Cardiol* 46: 1693–1701, 2005
- Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G: Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med* 353:999–1007, 2005
- Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ: Endothe-

- lial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. *Diabetes* 53:195–199, 2004
14. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC: Human endothelial progenitor cells from type 2 diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. *Circulation* 106:2781–2786, 2002
  15. Ii M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, Yoon YS, Wecker A, Luedemann C, Eaton E, Silver M, Thorne T, Losordo DW: Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. *Circ Res* 98:697–704, 2006
  16. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, Avogaro A: Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. *J Am Coll Cardiol* 45:1449–1457, 2005
  17. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Nat Med* 9:1370–1376, 2003
  18. Verma S, Kuliszewski MA, Li SH, Szmítko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. *Circulation* 109:2058–2067, 2004
  19. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. *Cell* 109:625–637, 2003
  20. Thum T, Fraccarollo D, Galuppo P, Tsikas T, Ertl G, Bauersachs J: Bone marrow molecular alterations after myocardial infarction: impact on endothelial progenitor cells. *Cardiovasc Res* 70:50–60, 2006
  21. Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B, Frosali F, Cosmi L, Maggi L, Lasagni L, Scheffold A, Kruger M, Dimmeler S, Marra F, Gensini G, Maggi E, Romagnani S: CD14+CD34 low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. *Circ Res* 97:314–322, 2005
  22. Fraccarollo D, Bauersachs J, Kellner M, Galuppo P, Ertl G: Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy. *Cardiovasc Res* 54:85–94, 2002
  23. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN Jr, Sunderman FW Jr: Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. *Clin Chem* 33:214–220, 1987
  24. Tsikas D, Mitschke A, Suchy MT, Gutzki FM, Stichtenoth DO: Determination of 3-nitrotyrosine in human urine at the basal state by gas chromatography-tandem mass spectrometry and evaluation of the excretion after oral intake. *J Chromatogr B Analyt Technol Biomed Life Sci* 827:146–156, 2005
  25. Fukushima T, Nixon JC: Analysis of reduced forms of biopterin in biological tissues and fluids. *Anal Biochem* 102:176–188, 1980
  26. Milstien S, Katusic Z: Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. *Biochem Biophys Res Commun* 263:681–684, 1999
  27. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A: Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. *Diabetes* 52:2795–804, 2003
  28. Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H: Protective role of endothelial nitric oxide synthase. *J Pathol* 199:8–17, 2003
  29. Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N: Enhanced atherosclerosis and kidney dysfunction in eNOS(-)/Apoe(-) mice are ameliorated by enalapril treatment. *J Clin Invest* 105:451–458, 2000
  30. Segal MS, Shah R, Afzal A, Perrault CM, Chang K, Schuler A, Beem E, Shaw LC, Li Calzi S, Harrison JK, Tran-Son-Tay R, Grant MB: Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. *Diabetes* 55:102–109, 2006
  31. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM: Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. *Arterioscler Thromb Vasc Biol* 24:445–450, 2004
  32. Landmesser U, Dikalov S, Price SR, McCann L, Fukui T, Holland SM, Mitch WE, Harrison DG: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest* 111:1201–1209, 2003
  33. Munzel T, Daiber A, Ullrich V, Mulsch A: Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. *Arterioscler Thromb Vasc Biol* 25:1551–1557, 2005
  34. Verhaar MC, Westerweel PE, van Zonneveld AJ, Rabelink TJ: Free radical production by dysfunctional eNOS. *Heart* 90:494–495, 2004
  35. Alp NJ, Channon KM: Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. *Arterioscler Thromb Vasc Biol* 24:413–420, 2004
  36. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. *Circulation* 96:25–28, 1997
  37. Cai S, Khoo J, Channon KM: Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. *Cardiovasc Res* 65:823–831, 2005
  38. Molnar J, Yu S, Mzhavia N, Pau C, Chereshnev I, Dansky HM: Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. *Circ Res* 96:1178–1184, 2005
  39. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. *Am J Physiol Renal Physiol* 288:1144–1152, 2005
  40. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S: Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. *J Biol Chem* 278:22546–22554, 2003
  41. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmeler S: Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. *Blood* 104:3591–3597, 2004
  42. Galasso G, Schiekofer S, Sato K, Shibata R, Handy DE, Ouchi N, Leopold JA, Loscalzo J, Walsh K: Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. *Circ Res* 98:254–261, 2006
  43. Haendeler J, Dimmeler S: Inseparably tied: functional and antioxidative capacity of endothelial progenitor cells. *Circ Res* 98:157–158, 2006
  44. Seeger FH, Haendeler J, Walter DH, Rochwalsky U, Reinhold J, Urbich C, Rossig L, Corbaz A, Chvatchko Y, Zeiher AM, Dimmeler S: p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. *Circulation* 111:1184–1191, 2005
  45. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D: Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. *Hypertension* 45:526–529, 2005
  46. Krankel N, Adams V, Linke A, Gielen S, Erbs S, Lenk K, Schuler G, Hambrecht R: Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. *Arterioscler Thromb Vasc Biol* 25:698–703, 2005
  47. Fox SW, Chow JW: Nitric oxide synthase expression in bone cells. *Bone* 23:1–6, 1998
  48. Zou MH, Shi C, Cohen RA: Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. *J Clin Invest* 109:817–826, 2002